<DOC>
	<DOCNO>NCT00019695</DOCNO>
	<brief_summary>RATIONALE : Ketoconazole may suppress production hormone may interfere growth prostate cancer cell . Alendronate sodium may effective prevent bone metastases bone pain associated prostate cancer . It known ketoconazole effective without alendronate sodium . PURPOSE : Randomized phase II trial study effectiveness ketoconazole without alendronate sodium treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Ketoconazole With Without Alendronate Sodium Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether evidence ketoconazole plus alendronate sodium produce acceptable disease response compare ketoconazole alone patient androgen-independent metastatic adenocarcinoma prostate . II . Characterize pharmacokinetics/pharmacodynamics ass bone marrow concentration agent . III . Assess matrix metalloproteinase ( MMP ) inhibition potential alendronate sodium monitoring marker angiogenesis , MMP breakdown , change hydroxyproline . PROTOCOL OUTLINE : This randomize , open-label study . Patients randomize one two treatment arm . Arm I : Patients receive single oral dose ketoconazole day 1 . Patients begin take ketoconazole 3 time per day day 8 . Arm II : Patients receive single oral dose alendronate sodium day 1 single oral dose ketoconazole day 3 . Patients begin take alendronate sodium every morning ketoconazole 3 time per day day 8 . Treatment continue arm absence unacceptable toxicity disease progression . Patients experience clinical complete remission ( CR ) receive treatment additional 60 day beyond documentation clinical CR . Patients follow every 2 month . PROJECTED ACCRUAL : A total 72 patient ( 36 per arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically confirm adenocarcinoma prostate Androgen independent least 1 bone lesion felt associate metastatic disease Refractory disease must demonstrate withdrawal flutamide , nilutamide , bicalutamide , antiandrogen Clinically progressive disease least 1 month document rise PSA level , least 1 new metastatic deposit Tc99 bone scintigraphy , increase measurable disease , new area malignant disease Patients PSAnegative disease ( i.e. , PSA le 10 ng/mL ) must positive CT scan soft tissue disease use disease staging , bone scan , form documentable disease progression ( i.e. , rise carcinoembryonic antigen , prostatic acid phosphatase ) Testosterone range expect castrate male No brain metastasis primary CNS malignancies No unresolved acute local complication require urgent local medical therapy ( severe bone pain , spinal cord compression , urinary flow obstruction ) Prior/Concurrent Therapy Biologic therapy : Not specify Chemotherapy : No prior ketoconazole prostate cancer Endocrine therapy : See Disease Characteristics Treatment LHRH agonist must continue patient undergone surgical castration If LHRH agonist discontinue , must reinstituted documented disease progression At least 4 week since prior hormonal therapy LHRH agonist recover Radiotherapy : Prior radiotherapy prostate allow At least 4 week since prior radiotherapy recover Surgery : Prior radical prostatectomy allow At least 4 week since prior surgery recover Other : At least 4 week since prior anticancer therapy recover No prior transfusion strontium chloride Sr 89 and/or samarium Sm 153 lexidronam pentasodium No concurrent phenytoin , theophylline , cisapride , triazolam , astemizole , loratadine , rifampin , isoniazid , erythromycin , terfenadine , midazolam , alprazolam , atorvastatin calcium , cerivastatin sodium , dofetilide , lovastatin , pimozide , simvastatin , sirolimus No concurrent drug decrease gastric acid output increase gastric pH ( e.g. , antacid , cimetidine , ranitidine , antimuscarinics ) No concurrent warfarin Patient Characteristics Age : 18 Performance status : ECOG 02 Life expectancy : Greater 3 month Hematopoietic : Granulocyte count least 1,000/mm3 Hemoglobin least 8.0 g/dL ( pretreatment transfusion allow , provide hemoglobin maintain 30 day without additional transfusion and/or active source bleeding identify treat ) Platelet count least 75,000/mm3 Hepatic : Acute care panel ( i.e. , electrolytes , BUN ) urinalysis normal Bilirubin great 1.2 mg/dL ALT le 2.5 time upper limit normal AST le 2.5 time normal Renal : Creatinine great 1.5 mg/dL proteinuria present OR Creatinine clearance great 40 mL/min proteinuria le 500 mg/day ( proteinuria exclusion patient stent place ) Cardiovascular : No history unstable newly diagnose angina pectoris No myocardial infarction within past 6 month No New York Heart Association class IIIV congestive heart failure Pulmonary : No chronic obstructive lung disease require oxygen therapy Neurologic : No uncontrolled seizure activity No history seizure within past 10 year Other : No prior malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ bladder No lifethreatening illnesses No untreated infection HIV negative Willingness travel home NIH followup visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2004</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>cancer</keyword>
	<keyword>cellular diagnosis , prostate cancer</keyword>
	<keyword>genetic condition</keyword>
	<keyword>male reproductive cancer</keyword>
	<keyword>metastatic cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>site , metastatic cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>stage , prostate cancer</keyword>
	<keyword>unclassified/other cancer</keyword>
</DOC>